<DOC>
	<DOCNO>NCT00150839</DOCNO>
	<brief_summary>The propose study randomize , placebo-controlled , double-blind trial evaluate safety efficacy antidepressant combination treatment depression . Depressive disorder one common human disease high burden every patient , her/his family , health care system society whole . Actual treatment concept depressive disorder include pharmacologic , biologic ( e.g . electroconvulsive therapy , light therapy ) psychologic therapy . Even though effective therapeutic option hand , therapy need time . It often possible reach full remission disease 10-25 % patient suffer depression regard `` treatment-resistant '' . In treatment resistant depression , use combination antidepressive drug consider safe effective . However , present data exist concern use drug combination primary therapeutic option . The aim study examine hypothesis , significantly patient achieve full remission depressive symptom treat combination two antidepressant secondary hypothesis , patient receive drug combination achieve remission faster patient treat monotherapy . To test hypothesis , two group parallel design use compare efficacy safety mirtazapine combination venlafaxine placebo .</brief_summary>
	<brief_title>Hippocampal Volume Young Patients With Major Depression Before After Combined Antidepressive Therapy</brief_title>
	<detailed_description>Background Information Combining antidepressants well-established medical procedure treatment therapy refractory depression , may also apply successfully non-refractory condition . The goal study test hypothesis . All participant treat Remergil Soltab® , sedative antidepressant contain mirtazapine . In double-blind , parallel-group design , participant treat either Trevilor® retard , antidepressant selective-serotonin-norepinephrine-reuptake-inhibitor class contain venlafaxine placebo . Especially treatment therapy-resistant depression augmentation- combination strategy widely use ( Demling Frieling 2004 ) . Only limited data exist efficacy safety combination antidepressant : Carpenter et al . show , adjunctive use mirtazapine add prior use antidepressant ( mostly SSRIs ) effective placebo ( Carpenter et al 2002 ) . Devarajan Dursun report effective antidepressive therapy combination citalopram reboxetine ( Devarajan Dursun 2000 ) . Rubio et al . find combination reboxetine , SSRI venlafaxine mirtazapine effective ( Rubio et al 2004 ) . Smith et al . report less side effect venlafaxine use combine mirtazapine . All mention study conduct treatment-resistant depression . Only study Carpenter et al . do randomize , control , double-blind design . No data exist efficacy safety combine antidepressant use primary therapy depression . Pallanti et al . able show , combination SSRI mirtazapine lead early onset therapeutic effect OCD ( Pallanti et al 2004 ) . There exist little evidence benefit combine antidepressant use depression . However , combination antidepressant prove effective safe treatment-resistant depression . All used antidepressant side-effects ( see `` Fachinformation '' detail ) . Drug-drug interaction describe drug use trial . A risk-potentiation therefore seem unlikely . Route administration : Venlafaxine placebo administer orally , usual mode administration antidepressive drug . Only Remergil Soltab®is administer use orodispersible tablet . This way administer mirtazapine proven effective . Dosage : All participant treat Remergil Soltab® 45mg , high dosage license Germany . Trevilor® retard use 300mg/d . It license 375mg/d , practicability reason , especially blind procedure , modestly low dosage entertain . Dosage regimen : Remergil® medication start 15mg two day randomization . On day 3 4 , 30mg use . From day 5 , 45mg use . In Trevilor® group , treatment start 150mg first three day , afterwards 300mg use . Beginning day 4 , group treat two capsule blind study medication . Treatment period : All patient treat 12 week double-blind fashion . The trial conduct compliance protocol , guideline good clinical practice ( CPMP/ICH/135/95 ) applicable regulatory requirement , namely German law drug ( AMG ) . Participants : 160 participant , female male recruit admitted open ward Department Psychiatry Psychotherapy , Universitätsklinikum Erlangen . Participants suffer depressive disorder need 18-65 year old . Treatment Subjects After screen inclusion trial , prior psychopharmacological medication stop wash . How dose reduction cessation do decide individually . The wash-out phase exceed 5-7 day . The use irreversible inhibitor monoamine oxidase ( MAOI ) 14 day prior screen exclusion criterion , wash-out period 14 day suitable trial . After wash-out , patient randomize two group : 1 . VENLA - Participants receive Trevilor®retard 150mg blind capsule . For three day , one capsule administer , afterwards two capsule administer , represent dosage 300mg/d . 2 . CONT - Participants receive placebo capsule . For three day , one capsule administer , afterwards two capsule administer . All participant receive Remergil Soltab® start 15mg two day , 30mg day 3 4 45mg begin day 5 Medication permit trial : non-psychiatric medication , lorazepam pipamperon . Medication permit : Antidepressants study medication , neuroleptic pipamperon , sedative lorazepam . Medication known interaction study medication ( accord SPC ) . All medication allow wash-out period trial exception irreversible MAO inhibitor ( MAOI ) . Medication permit trial : All medication allow trial . The use MAOI monoaminergic substance start earlier 14 day end intake study medication . Assessment Efficacy Efficacy assess use different psychometric scale either fill participant investigator . Scales use BDI , BAI , BSI , PSQuI questionaires fill participant CGI , MADR-S , HAM-D HAM-A rating scale fill investigator . During first week week 13 , cranial magnetic resonance image obtain , assess morphologic change brain . During weekly visit , BDI , BAI , CGI , HAM-D , HAM-A MADR-S entertain . BSI PSQuI entertain screen , visit 4 , visit 8 , visit 12 visit 13 . ( please see also attach flow chart 16 Supplement A detail ) .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Women men age 1855 year Moderate severe depressive episode accord ICD10criteria ICD10 : F32.1 , F32.2 , F33.1 , F33.2 ) MADRSsum value &gt; =18 point Bipolar affective disorder incl . BDII . Psychiatric neurologic comorbidity . Depression psychotic symptom . Pregnancy lactation period . Significant cardiovascular gastrointestinal disease . Severe dysfunction liver ( define accord ChildPughCriteria ( &gt; =Child A ) ) kidney ( define accord KDIGO stage I ( albuminuria &gt; =30mg/g ) . Known proven pharmacoresistance . Proven contraindication MRI ( e.g . pacemaker ) . Known incompatibility one substance use . Intake irreversible inhibitor monoamine oxidase ( MAOI , e.g . tranylcypromine ) last 14 day . Known phenylketonuria . Women childbearing potential use highly effective method birth control ( e.g . implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Depressive Disorder , Major</keyword>
	<keyword>Venlafaxine</keyword>
	<keyword>Mirtazapine</keyword>
	<keyword>Double-blind RCT</keyword>
	<keyword>Magnetic resonance imaging</keyword>
	<keyword>Hippocampal volume</keyword>
</DOC>